David Richard A. 4
4 · Qualigen Therapeutics, Inc. · Filed May 27, 2020
Insider Transaction Report
Form 4
David Richard A.
Director
Transactions
- Other
Warrant (Right to Buy)
2020-05-22+8,857→ 8,857 totalExercise: $2.54From: 2020-05-22Exp: 2027-06-26→ Common Stock (8,857 underlying)
Footnotes (2)
- [F1]On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became a director of the Issuer.
- [F2]Immediately prior to the Closing, the Reporting Person held Qualigen Series C convertible preferred stock warrants. Pursuant to the Merger, the Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.